Can you tell me your opinion on this line from a Hoffman slide back in January . (Or anyone who wants to chime in)
To me, I keep thinking they have already or are planning to add the ici combo in time for readouts by the end of this month.
What do you think?
It seems to me that a ctdna readout is only helpful in this case to determine if ici is working well.
https://x.com/MikeSheikh2/status/2011091504073445850/photo/2
From Slide:
"Initial PD-L1/ctDna readouts from mCRC trial
[1stQ 2026]
I asked AI
"is ctdna used to test pdl1 levels or to test ici success potential"
"Circulating tumor DNA (ctDNA) is primarily used to assess immune checkpoint inhibitor (ICI) success potential and monitor real-time treatment response. It is not used to test PD-L1 levels, which are typically measured through protein expression in tumor tissue biopsy.
Key differences in their clinical roles include:
ICI Success Potential & Monitoring: ctDNA is a dynamic biomarker. Decreases in ctDNA levels (known as ctDNA clearance) during treatment are strong predictors of a positive response to ICI therapy and long-term survival.
It can also help clinicians distinguish between "pseudoprogression" (temporary tumor swelling due to immune activity) and true disease progression.
PD-L1 Levels: PD-L1 is a static, tissue-based biomarker used primarily at the start of treatment to determine if a patient is a candidate for certain immunotherapies.
Combined Utility: While they are different tests, they are often used together. Studies show that combining PD-L1 expression data with early changes in ctDNA provides a more accurate tool for monitoring ICI response than using either marker alone.
To me, I keep thinking they have already or are planning to add the ici combo in time for readouts by the end of this month.
What do you think?
It seems to me that a ctdna readout is only helpful in this case to determine if ici is working well.
https://x.com/MikeSheikh2/status/2011091504073445850/photo/2
From Slide:
"Initial PD-L1/ctDna readouts from mCRC trial
[1stQ 2026]
I asked AI
"is ctdna used to test pdl1 levels or to test ici success potential"
"Circulating tumor DNA (ctDNA) is primarily used to assess immune checkpoint inhibitor (ICI) success potential and monitor real-time treatment response. It is not used to test PD-L1 levels, which are typically measured through protein expression in tumor tissue biopsy.
Key differences in their clinical roles include:
ICI Success Potential & Monitoring: ctDNA is a dynamic biomarker. Decreases in ctDNA levels (known as ctDNA clearance) during treatment are strong predictors of a positive response to ICI therapy and long-term survival.
It can also help clinicians distinguish between "pseudoprogression" (temporary tumor swelling due to immune activity) and true disease progression.
PD-L1 Levels: PD-L1 is a static, tissue-based biomarker used primarily at the start of treatment to determine if a patient is a candidate for certain immunotherapies.
Combined Utility: While they are different tests, they are often used together. Studies show that combining PD-L1 expression data with early changes in ctDNA provides a more accurate tool for monitoring ICI response than using either marker alone.
10
